These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 22580602

  • 1. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N.
    Oncogene; 2013 Mar 28; 32(13):1714-23. PubMed ID: 22580602
    [Abstract] [Full Text] [Related]

  • 2. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N, Vasseur R, Vincent A, Duchêne B, Van Seuningen I, Jonckheere N.
    Oncotarget; 2015 May 10; 6(13):10853-67. PubMed ID: 25890497
    [Abstract] [Full Text] [Related]

  • 3. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
    Sagar S, Leiphrakpam PD, Thomas D, McAndrews KL, Caffrey TC, Swanson BJ, Clausen H, Wandall HH, Hollingsworth MA, Radhakrishnan P.
    Cancer Lett; 2021 Apr 10; 503():91-102. PubMed ID: 33485947
    [Abstract] [Full Text] [Related]

  • 4. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
    García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M.
    Clin Cancer Res; 2003 Oct 15; 9(13):5000-8. PubMed ID: 14581375
    [Abstract] [Full Text] [Related]

  • 5. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.
    Cancer Chemother Pharmacol; 2010 Mar 15; 65(4):679-86. PubMed ID: 19639316
    [Abstract] [Full Text] [Related]

  • 6. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M, Zhang Y, Yang J, Cui X, Zhou Z, Zhan H, Ding K, Tian X, Yang Z, Fung KA, Edil BH, Postier RG, Bronze MS, Fernandez-Zapico ME, Stemmler MP, Brabletz T, Li YP, Houchen CW, Li M.
    Gastroenterology; 2020 Feb 15; 158(3):679-692.e1. PubMed ID: 31711924
    [Abstract] [Full Text] [Related]

  • 7. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
    Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, Van Laethem JL.
    Clin Cancer Res; 2009 Apr 15; 15(8):2913-9. PubMed ID: 19318496
    [Abstract] [Full Text] [Related]

  • 8. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR.
    Clin Cancer Res; 2004 Oct 15; 10(20):6956-61. PubMed ID: 15501974
    [Abstract] [Full Text] [Related]

  • 9. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC.
    Carcinogenesis; 2016 Nov 01; 37(11):1041-1051. PubMed ID: 27604902
    [Abstract] [Full Text] [Related]

  • 10. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 01; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 11. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
    Ansari D, Urey C, Hilmersson KS, Bauden MP, Ek F, Olsson R, Andersson R.
    Anticancer Res; 2014 Oct 01; 34(10):5269-76. PubMed ID: 25275019
    [Abstract] [Full Text] [Related]

  • 12. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
    Mimeault M, Johansson SL, Senapati S, Momi N, Chakraborty S, Batra SK.
    Cancer Lett; 2010 Sep 01; 295(1):69-84. PubMed ID: 20303649
    [Abstract] [Full Text] [Related]

  • 13. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
    Bafna S, Kaur S, Momi N, Batra SK.
    Br J Cancer; 2009 Oct 06; 101(7):1155-61. PubMed ID: 19738614
    [Abstract] [Full Text] [Related]

  • 14. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T.
    Surgery; 2013 Apr 06; 153(4):565-75. PubMed ID: 23253379
    [Abstract] [Full Text] [Related]

  • 15. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
    Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R.
    Cancer Res; 2011 Mar 01; 71(5):1825-35. PubMed ID: 21343396
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M, Pach R, Kulig P, Legutko J, Kulig J.
    Pancreas; 2017 Mar 01; 46(5):684-689. PubMed ID: 28196013
    [Abstract] [Full Text] [Related]

  • 17. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R.
    Cancer Sci; 2004 Sep 01; 95(9):753-7. PubMed ID: 15471562
    [Abstract] [Full Text] [Related]

  • 18. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y.
    Br J Cancer; 2007 Feb 12; 96(3):457-63. PubMed ID: 17224927
    [Abstract] [Full Text] [Related]

  • 19. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
    Urey C, Andersson B, Ansari D, Sasor A, Said-Hilmersson K, Nilsson J, Andersson R.
    Scand J Gastroenterol; 2017 May 12; 52(5):595-600. PubMed ID: 28270046
    [Abstract] [Full Text] [Related]

  • 20. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N, Okamoto A, Kamata Y, Misawa T, Uwagawa T, Gocho T, Yanaga K, Manome Y.
    Oncol Rep; 2010 Feb 12; 23(2):471-5. PubMed ID: 20043109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.